Positions 26–50 of 62.
Slightly embarrassed to be asking this, but: someone explain biopsy to me like I have not read a paper in years. Bought small because the evidence base is early. That…
hepatic fat is doing more work than we give it credit for. Making the case below, and I expect to lose some of it in the comments. Imaging-derived liver fat fraction is…
is it normal to get constipation at week 7, logged the same way every week so the comparison is at least internally fair. Assumed the weight numbers were the point and…
Check-in as promised in the title: small win: hepatic fat stopped being a problem at week 91. Nothing containing this compound is approved anywhere. Research-use-only…
Reference standards, analytical reagents and system-suitability material. If you are running your own method, start with a known.
Reference standardssomeone explain survodutide to me like I have not read a paper in years. I am not trying to be the "source?" guy. I would just like a source. Assumed the weight numbers…
Six-word version is the title — anyone else notice survodutide kicking in around week 93 — and the rest is context. Read the phase 2 hepatic paper properly and the…
4 months in and MASH is still the thing I get wrong. Numbers below. Ask me the boring questions, they are the useful ones. Numbers, in the order they matter: 4 months.…
WWB survo — Medutest came back 99.2% against a claimed 98.5%. One vial, one service, one member paying, which is the only kind of result this board should treat as…
why does nobody talk about dual agonist, and I want the answer with the reasoning attached rather than just the conclusion. Assumed the weight numbers were the point…
hepatic fat: the version I wish someone had shown me in week 1. Full detail below, and I have tried to keep the editorialising out of it. Bought small because the…
The phase 2 MASH results ( NEJM , 2024) are, to me, the most underdiscussed thing in this whole space. Biopsy-confirmed endpoints. Not an ALT screenshot, not imaging,…
Thinking out loud about this: three years of MASH threads, summarised so you do not have to read them. Spent an evening on the histology scoring system and understood…
MASH — my 24-week log, condensed into one table, which sounds obvious until you try to state the evidence for it. It is a dual agonist at the GLP-1 and glucagon…
Trying to get a straight answer on this: why does nobody talk about survodutide. Went slowly because everything published describes a deliberate escalation. That is the…
dual agonist is the most under-discussed thing on this board. I have gone back and forth on this for months. Phase 2 in a biopsy-confirmed population is a demanding…
Send the vial, get the number. Third-party purity and identity testing, results published to you regardless of what they say.
Test a vialSponsoredEst. 1998. ISO 9001 and cGMP, 1,500+ staff, 200+ patents. There is a fair chance the vial you are about to send for testing started here. Batch-specific COA as standard.
glbiochem.netShort public-service post: dual agonist is not what most of this community thinks it is. Asked here what the difference was between the imaging and biopsy endpoints and…
GGPeps survo — VendorInvestigate came back 97.9% against a claimed 97.0%, and before anyone asks: same batch throughout, single submission, no cherry-picking between…
Result first, context after: 8th independent test on JEEP — 97.2% on a claimed 97.0%, and the trend is the interesting part . Everything below is how it was ordered,…
three years of glucagon threads, summarised so you do not have to read them, which sounds obvious until you try to state the evidence for it. It is a dual agonist at…
MASH is doing more work than we give it credit for. Change my mind, genuinely — I have no stake in being right about this. Spent an evening on the histology scoring…
Something I keep coming back to: hepatic endpoints need biopsy data, not an ALT screenshot. Sent a vial to Janoshik because there was nothing on file. 98.4% against a…
Housekeeping: proposal — a flair for dual agonist posts. Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human…
survodutide MASH data is the most interesting hepatic readout in the class. Change my mind, genuinely — I have no stake in being right about this. Nothing containing…
The title is the whole question — does MASH actually matter or is it forum lore at this point — but here is why I am asking. Independent purity results for this…
The title is the whole question — am I the only one who found hepatic fat harder than the injections — but here is why I am asking. Independent purity results for this…
Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference